Dr. Megan Elizabeth Fracol, MD

Dr. Fracol practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Fracol's NPI, 1548656887, was assigned on April 14, 2015. Dr. Fracol holds Illinois license 036147886.

Dr. Fracol's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Fracol's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. Dr. Fracol is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Fracol to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fracol practices, 4 sites in all. Vendor and product names are available with a free account.

Plastic and reconstructive surgery is Dr. Fracol's primary specialty in the NPI Registry, under taxonomy code 2086S0122X. Dmand AI has Dr. Fracol's licenses on file in 2 states: Illinois and Texas.

CMS data shows 97 Medicare services from Dr. Fracol across 2 procedure codes in 2024, all of them office visits, for 98 Medicare patients. Medicare paid $5,543 for them. Every service was in an office.

CMS counts 98 Medicare patients who saw Dr. Fracol in 2024. The largest group is 65 to 74, with 46 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fracol's median patient age at 56, with 79% women.

In 2024, Dr. Fracol wrote 54 Medicare Part D claims for 27 patients. 83% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $262 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Fracol for performance year 2024, reported through an alternative payment model (APM). Dr. Fracol accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fracol as offering telehealth.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 44 papers to Dr. Fracol, published from 2013 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Breast Implantation and Breast Implants. Dr. Fracol has published most often in Plast Reconstr Surg. Dr. Fracol's most frequent co-authors are Gregory A. Dumanian, MD, Lauren Nicole Feld, DO and Jason Hyunsuk Ko, MD.

CMS Open Payments shows 56 general payments to Dr. Fracol from 19 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 90% of the total. Davol Inc. paid the most, $1,449.